{"content":"<li class=\"n-box-item date-title\" data-end=\"1352782799\" data-start=\"1352696400\" data-txt=\"Wednesday, December 18, 2019\">Monday, November 12, 2012</li><li class=\"n-box-item sa-box-item\" data-id=\"660021\" data-ts=\"1352761162\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WFT\" target=\"_blank\">WFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/660021\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weatherford (NYSE:WFT) reports preliminary Q3 earnings of ~$0.20/share vs. $0.29 analyst...</a></h4><p>Weatherford (NYSE:<a href=\"https://seekingalpha.com/symbol/WFT\" title=\"Weatherford International Ltd.\">WFT</a>) reports preliminary Q3 earnings of ~$0.20/share vs. $0.29 analyst consensus, and revenues of $3.82B vs. $3.89B analyst consensus. WFT also restates previously reported results for Q1 and revises Q2 results to correct errors in  revenue and operating income amounts associated with a percentage of completion contract. Shares <font color=\"red\">-4.9%</font> AH.</p><div class=\"tiny-share-widget\" data-id=\"660021\" data-linked=\"Weatherford (NYSE:WFT) reports preliminary Q3 earnings of ~$0.20/share vs. $0.29 analyst...\" data-tweet=\"$WFT $WFTIQ - Weatherford (NYSE:WFT) reports preliminary Q3 earnings of ~$0.20/share vs. $0.29 analyst consensus, and revenues of $3.82B vs. $3.89B analyst consensus. WFT also restates previously reported results for Q1 and revises Q2 results to correct... https://seekingalpha.com/news/660021?source=tweet\" data-url=\"https://seekingalpha.com/news/660021\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659991\" data-ts=\"1352760316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDGL\" target=\"_blank\">MDGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659991\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After-hours top gainers, as of 5:15 p.m.: SNTA +19.8%. IQNT +18.7%. LPH +10.2%. TSPT +8.9%. CSOD...</a></h4><b>After-hours top gainers, as of 5:15 p.m.:</b> SNTA <font color=\"green\">+19.8%</font>. <a href='https://seekingalpha.com/symbol/IQNT' title='Inteliquent, Inc.'>IQNT</a> <font color=\"green\">+18.7%</font>. LPH <font color=\"green\">+10.2%</font>. TSPT <font color=\"green\">+8.9%</font>. <a href='https://seekingalpha.com/symbol/CSOD' title='Cornerstone OnDemand, Inc.'>CSOD</a> <font color=\"green\">+8.1%</font>.   <br /><b>After-hours top losers:</b> <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color=\"red\">-8.6%</font>. <a href='https://seekingalpha.com/symbol/SCLN' title='SciClone Pharmaceuticals, Inc.'>SCLN</a> <font color=\"red\">-5.5%</font>. <a href='https://seekingalpha.com/symbol/EVER-OLD' title='EverBank Financial'>EVER-OLD</a> <font color=\"red\">-4.4%</font>. <a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a> <font color=\"red\">-4.1%</font>. <a href='https://seekingalpha.com/symbol/MWE' title='MarkWest Energy Partners, L.P.'>MWE</a> <font color=\"red\">-3.7%</font>.<div class=\"tiny-share-widget\" data-id=\"659991\" data-linked=\"After-hours top gainers, as of 5:15 p.m.: SNTA +19.8%. IQNT +18.7%. LPH +10.2%. TSPT +8.9%. CSOD...\" data-tweet=\"$MDGL $MDGL $IQNT - After-hours top gainers, as of 5:15 p.m.: SNTA +19.8%. IQNT +18.7%. LPH +10.2%. TSPT +8.9%. CSOD +8.1%. After-hours top losers: INFI -8.6%. SCLN -5.5%. EVER-OLD -4.4%. GME -4.1%. MWE -3.7%. https://seekingalpha.com/news/659991?source=tweet\" data-url=\"https://seekingalpha.com/news/659991\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659881\" data-ts=\"1352757432\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRML\" target=\"_blank\">VRML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659881\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Vermillion (NASDAQ:VRML): Q3 beats bottom line consensus on lower-than-anticipated...</a></h4><p>More on Vermillion (NASDAQ:<a href=\"https://seekingalpha.com/symbol/VRML\" title=\"Vermillion, Inc.\">VRML</a>): <a target=\"_blank\" href=\"https://seekingalpha.com/market_currents/post/659751\">Q3 beats</a> bottom line consensus on lower-than-anticipated losses. Revenue was flat on a Y/Y basis, while earnings got a big boost from better cost controls. Operating expenses decreased by nearly half as compared to the prior year period, driven by lower clinical trial costs, fewer legal expenses and ongoing cost containment initiatives. Shares <font color=\"green\">+7.5%</font> AH.</p><div class=\"tiny-share-widget\" data-id=\"659881\" data-linked=\"More on Vermillion (NASDAQ:VRML): Q3 beats bottom line consensus on lower-than-anticipated...\" data-tweet=\"$VRML - More on Vermillion (NASDAQ:VRML): Q3 beats bottom line consensus on lower-than-anticipated losses. Revenue was flat on a Y/Y basis, while earnings got a big boost from better cost controls. Operating expenses decreased by nearly half as compared... https://seekingalpha.com/news/659881?source=tweet\" data-url=\"https://seekingalpha.com/news/659881\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659871\" data-ts=\"1352757094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LKM\" target=\"_blank\">LKM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659871\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on NetQin: Q4 guidance is for revenue of $28.5M-$29.5M, above a $27.8M consensus. 2013...</a></h4><p>More on <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/659591\">NetQin</a>: Q4 guidance is for revenue of $28.5M-$29.5M, above a $27.8M consensus. 2013 revenue guidance set at $150M-$155M, above a $144.6M consensus. NetQin is acquiring Feiliu, a Chinese mobile community platform with 12M monthly users, for 6.2M shares (current value of $41.5M) - NetQin already owns a 21.2% stake. Deferred revenue rose 14.7% Q/Q in Q3 to $10.9M. Registered accounts rose by 38.1M to 241.6M (141.9M in China, 99.7M overseas). NQ <font color=\"green\">+3.6%</font> AH.Â  CC at 8PM ET (<a target=\"_blank\" href=\"http://www.media-server.com/m/p/s8846p95\">webcast</a>). (PR)</p><div class=\"tiny-share-widget\" data-id=\"659871\" data-linked=\"More on NetQin: Q4 guidance is for revenue of $28.5M-$29.5M, above a $27.8M consensus. 2013...\" data-tweet=\"$LKM - More on NetQin: Q4 guidance is for revenue of $28.5M-$29.5M, above a $27.8M consensus. 2013 revenue guidance set at $150M-$155M, above a $144.6M consensus. NetQin is acquiring Feiliu, a Chinese mobile community platform with 12M monthly users, fo... https://seekingalpha.com/news/659871?source=tweet\" data-url=\"https://seekingalpha.com/news/659871\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659821\" data-ts=\"1352756819\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTK\" target=\"_blank\">PRTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659821\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Transcept Pharmaceuticals (TSPT): Q3 easily beats estimates across the board. Revenue...</a></h4>More on Transcept Pharmaceuticals (TSPT): <a target=\"_blank\" href=\"https://seekingalpha.com/market_currents/post/659711\" target=\"_blank\">Q3 easily beats</a> estimates across the board. Revenue topped consensus expectations, boosted in part by a $10M milestone payment from Purdue Pharmaceutical for the listing of a TSPT method of use patent in the FDA's  Orange Book, while better EPS performance was driven by lower R&amp;D expenses. Shares <font color=\"green\">+3.5%</font> AH.<div class=\"tiny-share-widget\" data-id=\"659821\" data-linked=\"More on Transcept Pharmaceuticals (TSPT): Q3 easily beats estimates across the board. Revenue...\" data-tweet=\"$PRTK - More on Transcept Pharmaceuticals (TSPT): Q3 easily beats estimates across the board. Revenue topped consensus expectations, boosted in part by a $10M milestone payment from Purdue Pharmaceutical for the listing of a TSPT method of use patent in... https://seekingalpha.com/news/659821?source=tweet\" data-url=\"https://seekingalpha.com/news/659821\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659711\" data-ts=\"1352755740\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTK\" target=\"_blank\">PRTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659711\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Transcept Pharmaceuticals (TSPT): Q3 EPS of $0.25 beats by $0.20. Revenue of $10.4M beats by...</a></h4><b>Transcept Pharmaceuticals (TSPT):</b> Q3 EPS of $0.25 <font color=\"green\">beats by $0.20</font>. Revenue of $10.4M <font color=\"green\">beats by $2M</font>. Shares <font color=\"green\">+3.5%</font> AH. (PR)<div class=\"tiny-share-widget\" data-id=\"659711\" data-linked=\"Transcept Pharmaceuticals (TSPT): Q3 EPS of $0.25 beats by $0.20. Revenue of $10.4M beats by...\" data-tweet=\"$PRTK - Transcept Pharmaceuticals (TSPT): Q3 EPS of $0.25 beats by $0.20. Revenue of $10.4M beats by $2M. Shares +3.5% AH. (PR) https://seekingalpha.com/news/659711?source=tweet\" data-url=\"https://seekingalpha.com/news/659711\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659691\" data-ts=\"1352755670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MWE\" target=\"_blank\">MWE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659691\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mark West Energy Partners (NYSE:MWE) -3.5% AH after announcing a public offering of 8.5M common...</a></h4><p>Mark West Energy Partners (NYSE:<a href=\"https://seekingalpha.com/symbol/MWE\" title=\"MarkWest Energy Partners, L.P.\">MWE</a>) <font color=\"red\">-3.5%</font> AH after announcing a public offering of 8.5M common units. MWE intends to use the net proceeds from the offering to fund its capital expenditure program, for general working capital and for other general partnership purposes.</p><div class=\"tiny-share-widget\" data-id=\"659691\" data-linked=\"Mark West Energy Partners (NYSE:MWE) -3.5% AH after announcing a public offering of 8.5M common...\" data-tweet=\"$MWE - Mark West Energy Partners (NYSE:MWE) -3.5% AH after announcing a public offering of 8.5M common units. MWE intends to use the net proceeds from the offering to fund its capital expenditure program, for general working capital and for other genera... https://seekingalpha.com/news/659691?source=tweet\" data-url=\"https://seekingalpha.com/news/659691\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659611\" data-ts=\"1352755101\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEIX\" target=\"_blank\">PEIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659611\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacific Ethanol (NASDAQ:PEIX): Q3 EPS of -$0.05. Revenue of $215.9M (-20% Y/Y). Shares -3.8% AH....</a></h4><b>Pacific Ethanol (NASDAQ:<a href=\"https://seekingalpha.com/symbol/PEIX\" title=\"Pacific Ethanol, Inc.\">PEIX</a>):</b> Q3 EPS of -$0.05. Revenue of $215.9M (-20% Y/Y). Shares <font color=\"red\">-3.8%</font> AH. (PR)<div class=\"tiny-share-widget\" data-id=\"659611\" data-linked=\"Pacific Ethanol (NASDAQ:PEIX): Q3 EPS of -$0.05. Revenue of $215.9M (-20% Y/Y). Shares -3.8% AH....\" data-tweet=\"$PEIX - Pacific Ethanol (NASDAQ:PEIX): Q3 EPS of -$0.05. Revenue of $215.9M (-20% Y/Y). Shares -3.8% AH. (PR) https://seekingalpha.com/news/659611?source=tweet\" data-url=\"https://seekingalpha.com/news/659611\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659581\" data-ts=\"1352754690\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VZ\" target=\"_blank\">VZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659581\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verizon Wireless says it will distribute an aggregate $8.5B to 55% owner Verizon (NYSE:VZ) and...</a></h4><p>Verizon Wireless says it will distribute an aggregate $8.5B to 55% owner Verizon (NYSE:<a href=\"https://seekingalpha.com/symbol/VZ\" title=\"Verizon Communications\">VZ</a>) and 45% owner Vodafone (NASDAQ:<a href=\"https://seekingalpha.com/symbol/VOD\" title=\"Vodafone Group Plc\">VOD</a>) by year's end. A <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/84650\">$10B distribution</a> was made last year, but Verizon had been non-committal until now about a follow-up. <a href=\"https://seekingalpha.com/symbol/VOD\" title=\"Vodafone Group Plc\">VOD</a> <font color=\"green\">+2.2%</font> AH. <a href=\"https://seekingalpha.com/symbol/VZ\" title=\"Verizon Communications\">VZ</a> <font color=\"green\">+0.2%</font>. (PR)</p><div class=\"tiny-share-widget\" data-id=\"659581\" data-linked=\"Verizon Wireless says it will distribute an aggregate $8.5B to 55% owner Verizon (NYSE:VZ) and...\" data-tweet=\"$VZ $VZ $VOD - Verizon Wireless says it will distribute an aggregate $8.5B to 55% owner Verizon (NYSE:VZ) and 45% owner Vodafone (NASDAQ:VOD) by year&#39;s end. A $10B distribution was made last year, but Verizon had been non-committal until now about a fol... https://seekingalpha.com/news/659581?source=tweet\" data-url=\"https://seekingalpha.com/news/659581\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659571\" data-ts=\"1352754649\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESE\" target=\"_blank\">ESE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659571\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ESCO Technologies (NYSE:ESE): FQ4 EPS of $0.65 beats by $0.03. Revenue of $192.2M (flat% Y/Y)...</a></h4><b>ESCO Technologies (NYSE:<a href=\"https://seekingalpha.com/symbol/ESE\" title=\"ESCO Technologies Inc.\">ESE</a>):</b> FQ4 EPS of $0.65 <font color=\"green\">beats by $0.03</font>. Revenue of $192.2M (flat% Y/Y) misses by $2.5M. Shares <font color=\"red\">-3.2%</font> AH. (PR)<div class=\"tiny-share-widget\" data-id=\"659571\" data-linked=\"ESCO Technologies (NYSE:ESE): FQ4 EPS of $0.65 beats by $0.03. Revenue of $192.2M (flat% Y/Y)...\" data-tweet=\"$ESE - ESCO Technologies (NYSE:ESE): FQ4 EPS of $0.65 beats by $0.03. Revenue of $192.2M (flat% Y/Y) misses by $2.5M. Shares -3.2% AH. (PR) https://seekingalpha.com/news/659571?source=tweet\" data-url=\"https://seekingalpha.com/news/659571\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659551\" data-ts=\"1352754477\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSOD\" target=\"_blank\">CSOD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659551\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cornerstone OnDemand (NASDAQ:CSOD): Q3 EPS of -$0.07 misses by $0.01. Revenue of $588.5M (+54%...</a></h4><b>Cornerstone OnDemand (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CSOD\" title=\"Cornerstone OnDemand, Inc.\">CSOD</a>):</b> Q3 EPS of -$0.07 <font color=\"red\">misses by $0.01</font>. Revenue of $588.5M (+54% Y/Y) <font color=\"green\">beats by $7M</font>. Shares <font color=\"green\">+2.7%</font> AH. (PR)<div class=\"tiny-share-widget\" data-id=\"659551\" data-linked=\"Cornerstone OnDemand (NASDAQ:CSOD): Q3 EPS of -$0.07 misses by $0.01. Revenue of $588.5M (+54%...\" data-tweet=\"$CSOD - Cornerstone OnDemand (NASDAQ:CSOD): Q3 EPS of -$0.07 misses by $0.01. Revenue of $588.5M (+54% Y/Y) beats by $7M. Shares +2.7% AH. (PR) https://seekingalpha.com/news/659551?source=tweet\" data-url=\"https://seekingalpha.com/news/659551\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659541\" data-ts=\"1352754386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAGL\" target=\"_blank\">BAGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659541\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Einstein Noah Restaurant (NASDAQ:BAGL): Q3 EPS of $0.20 in-line. Revenue of $105.5M (+1.9% Y/Y)...</a></h4><b>Einstein Noah Restaurant (NASDAQ:<a href=\"https://seekingalpha.com/symbol/BAGL\" title=\"Einstein Noah Restaurant Group, Inc.\">BAGL</a>):</b> Q3 EPS of $0.20 in-line. Revenue of $105.5M (+1.9% Y/Y) <font color=\"red\">misses by $0.8M</font>. Shares <font color=\"red\">-1.2%</font> AH. (PR)<div class=\"tiny-share-widget\" data-id=\"659541\" data-linked=\"Einstein Noah Restaurant (NASDAQ:BAGL): Q3 EPS of $0.20 in-line. Revenue of $105.5M (+1.9% Y/Y)...\" data-tweet=\"$BAGL - Einstein Noah Restaurant (NASDAQ:BAGL): Q3 EPS of $0.20 in-line. Revenue of $105.5M (+1.9% Y/Y) misses by $0.8M. Shares -1.2% AH. (PR) https://seekingalpha.com/news/659541?source=tweet\" data-url=\"https://seekingalpha.com/news/659541\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659531\" data-ts=\"1352754314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659531\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Video game stocks closed higher as Microsoft (NASDAQ:MSFT) announces it sold $220M worth of...</a></h4>Video game stocks closed higher as Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) announces it <a target=\"_blank\" href=\"http://venturebeat.com/2012/11/12/halo-4-sold-220m-in-its-first-24-hours/#o6zsVHFKdbbuQekV.99\" target=\"_blank\">sold $220M</a> worth of copies of the <a target=\"_blank\" href=\"http://www.metacritic.com/game/xbox-360/halo-4/critic-reviews\" target=\"_blank\">favorably-reviewed</a> <em>Halo 4</em> in its first 24 hours of availability, and expects to sell over $300M in in the first week. Though <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/656701\" target=\"_blank\">industry data</a> remains bleak, hopes have grown that the holiday season will be relatively strong thanks to a healthy lineup of new titles. <a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a> <font color=\"green\">+1%</font> <a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc'>ATVI</a> <font color=\"green\">+1.1%</font>. <a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a> <font color=\"green\">+3.8%</font>. <a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a> <font color=\"green\">+4.4%</font>.<div class=\"tiny-share-widget\" data-id=\"659531\" data-linked=\"Video game stocks closed higher as Microsoft (NASDAQ:MSFT) announces it sold $220M worth of...\" data-tweet=\"$MSFT $MSFT $EA - Video game stocks closed higher as Microsoft (NASDAQ:MSFT) announces it sold $220M worth of copies of the favorably-reviewed Halo 4 in its first 24 hours of availability, and expects to sell over $300M in in the first week. Though indu... https://seekingalpha.com/news/659531?source=tweet\" data-url=\"https://seekingalpha.com/news/659531\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659521\" data-ts=\"1352754299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HOLX\" target=\"_blank\">HOLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659521\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hologic (NASDAQ:HOLX): FQ4 EPS of $0.37 beats by $0.01. Revenue of $588M beats by $7M. Shares...</a></h4><b>Hologic (NASDAQ:<a href=\"https://seekingalpha.com/symbol/HOLX\" title=\"Hologic, Inc.\">HOLX</a>):</b> FQ4 EPS of $0.37 <font color=\"green\">beats by $0.01</font>. Revenue of $588M <font color=\"green\">beats by $7M</font>. Shares <font color=\"red\">-1.4%</font> AH. (PR)<div class=\"tiny-share-widget\" data-id=\"659521\" data-linked=\"Hologic (NASDAQ:HOLX): FQ4 EPS of $0.37 beats by $0.01. Revenue of $588M beats by $7M. Shares...\" data-tweet=\"$HOLX - Hologic (NASDAQ:HOLX): FQ4 EPS of $0.37 beats by $0.01. Revenue of $588M beats by $7M. Shares -1.4% AH. (PR) https://seekingalpha.com/news/659521?source=tweet\" data-url=\"https://seekingalpha.com/news/659521\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659461\" data-ts=\"1352753135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCY\" target=\"_blank\">ONCY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659461\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oncolytics Biotech (ONCY -2%) says it&#39;s appointed Kirk Look as it&#39;s new chief financial officer....</a></h4><p>Oncolytics Biotech (<a href=\"https://seekingalpha.com/symbol/ONCY\" title=\"Oncolytics Biotech Inc.\">ONCY</a> <font color=\"red\">-2%</font>) says it's appointed Kirk Look as it's new chief financial officer. Mr. Look has served as <a href=\"https://seekingalpha.com/symbol/ONCY\" title=\"Oncolytics Biotech Inc.\">ONCY</a>'s controller since 2003.</p><div class=\"tiny-share-widget\" data-id=\"659461\" data-linked=\"Oncolytics Biotech (ONCY -2%) says it&#39;s appointed Kirk Look as it&#39;s new chief financial officer....\" data-tweet=\"$ONCY - Oncolytics Biotech (ONCY -2%) says it&#39;s appointed Kirk Look as it&#39;s new chief financial officer. Mr. Look has served as ONCY&#39;s controller since 2003. https://seekingalpha.com/news/659461?source=tweet\" data-url=\"https://seekingalpha.com/news/659461\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659441\" data-ts=\"1352752708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659441\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shares of NuPathe (PATH -2%) are lower today after reporting a Q3 loss of $0.42 per share, below...</a></h4><p>Shares of NuPathe (<a href=\"https://seekingalpha.com/symbol/PATH\" title=\"\">PATH</a> <font color=\"red\">-2%</font>) are lower today after reporting a Q3 loss of $0.42 per share, below the Street consensus of a $0.36 per share loss. The company didn't report revenues for the quarter, which was expected. On a per share basis, earnings sank 29% Y/Y as the company's bottom line was negatively impacted by higher costs associated with separation expenses related to the resignation of its former CEO as well as the elimination of 15 full-time positions.</p><div class=\"tiny-share-widget\" data-id=\"659441\" data-linked=\"Shares of NuPathe (PATH -2%) are lower today after reporting a Q3 loss of $0.42 per share, below...\" data-tweet=\"$TEVA - Shares of NuPathe (PATH -2%) are lower today after reporting a Q3 loss of $0.42 per share, below the Street consensus of a $0.36 per share loss. The company didn&#39;t report revenues for the quarter, which was expected. On a per share basis, earnin... https://seekingalpha.com/news/659441?source=tweet\" data-url=\"https://seekingalpha.com/news/659441\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659381\" data-ts=\"1352751341\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDIX\" target=\"_blank\">IDIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659381\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Another antiviral drug maker focused on treating Hepatitis C that&#39;s experiencing a solid run...</a></h4><p>Another antiviral drug maker focused on treating Hepatitis C that's experiencing a solid run higher today is Idenix Pharmaceutical (<a href=\"https://seekingalpha.com/symbol/IDIX\" title=\"Idenix Pharmaceuticals, Inc.\">IDIX</a> <font color=\"green\">+11.5%</font>). On Saturday, the company announced positive study results for its clinical-stage hep C drug candidates \u2013 IDX719 and IDX184, and presented updated cardiovascular safety and antiviral activity data from phase IIb studies of IDX184. The results were presented at the Annual Meeting for the American Association for the Study of Liver Diseases in Boston.</p><div class=\"tiny-share-widget\" data-id=\"659381\" data-linked=\"Another antiviral drug maker focused on treating Hepatitis C that&#39;s experiencing a solid run...\" data-tweet=\"$IDIX - Another antiviral drug maker focused on treating Hepatitis C that&#39;s experiencing a solid run higher today is Idenix Pharmaceutical (IDIX +11.5%). On Saturday, the company announced positive study results for its clinical-stage hep C drug candida... https://seekingalpha.com/news/659381?source=tweet\" data-url=\"https://seekingalpha.com/news/659381\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659371\" data-ts=\"1352751241\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRLG\" target=\"_blank\">TRLG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659371\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">True Religion (TRLG +2.5%) catches a bid as the company gets lined up as a possible acquisition...</a></h4><p>True Religion (<a href=\"https://seekingalpha.com/symbol/TRLG\" title=\"True Religion Apparel, Inc.\">TRLG</a> <font color=\"green\">+2.5%</font>) <a target=\"_blank\" href=\"http://www.streetinsider.com/Rumors/True+Religion+%28TRLG%29+Higher+as+Foreign+Firms+Said+to+Be+Interested+in+Deal/7866574.html\">catches a bid</a> as the company gets lined up as a possible acquisition target of foreign retailers. The appeal of True Religion is that it has a footprint on six continents, but as of late it has been off-target with a number of its fashion lines.</p><div class=\"tiny-share-widget\" data-id=\"659371\" data-linked=\"True Religion (TRLG +2.5%) catches a bid as the company gets lined up as a possible acquisition...\" data-tweet=\"$TRLG - True Religion (TRLG +2.5%) catches a bid as the company gets lined up as a possible acquisition target of foreign retailers. The appeal of True Religion is that it has a footprint on six continents, but as of late it has been off-target with a n... https://seekingalpha.com/news/659371?source=tweet\" data-url=\"https://seekingalpha.com/news/659371\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659351\" data-ts=\"1352750471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LDK\" target=\"_blank\">LDK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659351\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Solar stocks advance as China says it is taking new applications from regional governments...</a></h4><p>Solar stocks advance as China says it is <a target=\"_blank\" href=\"http://www.bloomberg.com/news/2012-11-12/china-calls-for-solar-applications-eligible-for-subsidies.html\">taking new applications</a> from regional governments looking for solar project subsidies. Talk of a government bailout gives these shares a reprieve, but <a target=\"_blank\" href=\"http://blogs.barrons.com/emergingmarketsdaily/2012/11/12/chinese-solar-stocks-soar-on-subsidies/\">how long it lasts</a> is another story as many analysts think the industry needs more than this type of bailout. <a href=\"https://seekingalpha.com/symbol/LDK\" title=\"LDK Solar Co., Ltd.\">LDK</a> <font color=\"green\">+16.6%</font>, <a href=\"https://seekingalpha.com/symbol/STP\" title=\"Suntech Power Holdings Co., Ltd.\">STP</a> <font color=\"green\">+6.5%</font>, <a href=\"https://seekingalpha.com/symbol/YGE\" title=\"Yingli Green Energy Holding Company Limited\">YGE</a> <font color=\"green\">+3.7%</font>, <a href=\"https://seekingalpha.com/symbol/FSLR\" title=\"First Solar, Inc.\">FSLR</a> <font color=\"green\">+3%</font>.</p><div class=\"tiny-share-widget\" data-id=\"659351\" data-linked=\"Solar stocks advance as China says it is taking new applications from regional governments...\" data-tweet=\"$LDK $LDK $STP - Solar stocks advance as China says it is taking new applications from regional governments looking for solar project subsidies. Talk of a government bailout gives these shares a reprieve, but how long it lasts is another story as many a... https://seekingalpha.com/news/659351?source=tweet\" data-url=\"https://seekingalpha.com/news/659351\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659321\" data-ts=\"1352749703\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCP\" target=\"_blank\">PCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659321\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Precision Castparts (PCP +4.5%) deal to acquire Titanium Metals (TIE +42.4%) has a &amp;ldquo;go...</a></h4><p>The Precision Castparts (<a href=\"https://seekingalpha.com/symbol/PCP\" title=\"Precision Castparts Corp.\">PCP</a> <font color=\"green\">+4.5%</font>) <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/658241\">deal to acquire</a> Titanium Metals (TIE <font color=\"green\">+42.4%</font>) has a \u201cgo shop\" provision, allowing a TIE committee to solicit higher bids for 45 days, but D.A. Davidson <a target=\"_blank\" href=\"http://blogs.barrons.com/stockstowatchtoday/2012/11/12/expect-titanium-metals-deal-to-go-through-despite-go-shop-provision-analyts/\">sees the deal going through</a>, believing the timing of the deal is driven by uncertainty about capital gains taxes in 2013, with \"every incentive to get it done before the year end.\"</p><div class=\"tiny-share-widget\" data-id=\"659321\" data-linked=\"The Precision Castparts (PCP +4.5%) deal to acquire Titanium Metals (TIE +42.4%) has a \u201cgo shop&quot;...\" data-tweet=\"$PCP - The Precision Castparts (PCP +4.5%) deal to acquire Titanium Metals (TIE +42.4%) has a \u201cgo shop&quot; provision, allowing a TIE committee to solicit higher bids for 45 days, but D.A. Davidson sees the deal going through, believing the timing of the de... https://seekingalpha.com/news/659321?source=tweet\" data-url=\"https://seekingalpha.com/news/659321\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659301\" data-ts=\"1352749325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659301\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vertex (VRTX -1.4%) dips on an earlier downgrade to Neutral at Credit Suisse, citing lower sales...</a></h4><p>Vertex (<a href=\"https://seekingalpha.com/symbol/VRTX\" title=\"Vertex Pharmaceuticals Incorporated\">VRTX</a> <font color=\"red\">-1.4%</font>) dips on an earlier <a target=\"_blank\" href=\"http://www.streetinsider.com/Downgrades/Credit+Suisse+Downgrades+Vertex+%28VRTX%29+to+Neutral/7865156.html\">downgrade to Neutral</a> at Credit Suisse, citing lower sales forecasts for Incivek given Gilead (NASDAQ:<a href=\"https://seekingalpha.com/symbol/GILD\" title=\"Gilead Sciences, Inc.\">GILD</a>) new competition and expectations for significant warehousing pressure on margins. The firm also lowers its price target to $48 from $56.</p><div class=\"tiny-share-widget\" data-id=\"659301\" data-linked=\"Vertex (VRTX -1.4%) dips on an earlier downgrade to Neutral at Credit Suisse, citing lower sales...\" data-tweet=\"$VRTX $VRTX $GILD - Vertex (VRTX -1.4%) dips on an earlier downgrade to Neutral at Credit Suisse, citing lower sales forecasts for Incivek given Gilead (NASDAQ:GILD) new competition and expectations for significant warehousing pressure on margins. The f... https://seekingalpha.com/news/659301?source=tweet\" data-url=\"https://seekingalpha.com/news/659301\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659281\" data-ts=\"1352748833\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRAY\" target=\"_blank\">CRAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659281\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cray (CRAY +3.1%) is rallying after the DOE&#39;s Titan supercomputer, which was built by Cray, is...</a></h4>Cray (<a href='https://seekingalpha.com/symbol/CRAY' title='Cray Inc'>CRAY</a> <font color=\"green\">+3.1%</font>) is rallying after the DOE's Titan supercomputer, which was <a target=\"_blank\" href=\"http://investors.cray.com/phoenix.zhtml?c=98390&amp;p=irol-newsArticle&amp;ID=1750839\" target=\"_blank\">built by Cray</a>, is declared the world's most powerful system, dethroning the IBM-built Sequoia. <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/631971\" target=\"_blank\">Titan uses</a> AMD Opteron server CPUs and Nvidia's (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) K20 graphics accelerator, which was <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/658861\" target=\"_blank\">officially announced</a> today.<div class=\"tiny-share-widget\" data-id=\"659281\" data-linked=\"Cray (CRAY +3.1%) is rallying after the DOE&#39;s Titan supercomputer, which was built by Cray, is...\" data-tweet=\"$CRAY $CRAY $NVDA - Cray (CRAY +3.1%) is rallying after the DOE&#39;s Titan supercomputer, which was built by Cray, is declared the world&#39;s most powerful system, dethroning the IBM-built Sequoia. Titan uses AMD Opteron server CPUs and Nvidia&#39;s (NASDAQ:NVDA)... https://seekingalpha.com/news/659281?source=tweet\" data-url=\"https://seekingalpha.com/news/659281\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659261\" data-ts=\"1352748153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGO\" target=\"_blank\">EGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659261\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eldorado Gold (EGO -2.2%) is seeing higher costs but Haywood Securities expects lower costs and...</a></h4><p>Eldorado Gold (<a href=\"https://seekingalpha.com/symbol/EGO\" title=\"Eldorado Gold Corporation\">EGO</a> <font color=\"red\">-2.2%</font>) is seeing higher costs but Haywood Securities <a target=\"_blank\" href=\"http://www.northernminer.com/news/eldorado-gold-sees-higher-costs-in-q3/1001833708/?type=HotSectors\">expects lower costs and higher margins</a> as it works out issues at its mines and brings low-Â­cost operations online; with the addition of Eastern Dragon, Perama Hill and Skouries, EGO should achieve production of 1.5M oz. in 2015 at below $300/oz. EGO also announces the launch of an offering of up to $500M in senior notes.</p><div class=\"tiny-share-widget\" data-id=\"659261\" data-linked=\"Eldorado Gold (EGO -2.2%) is seeing higher costs but Haywood Securities expects lower costs and...\" data-tweet=\"$EGO - Eldorado Gold (EGO -2.2%) is seeing higher costs but Haywood Securities expects lower costs and higher margins as it works out issues at its mines and brings low-Â­cost operations online; with the addition of Eastern Dragon, Perama Hill and Skouri... https://seekingalpha.com/news/659261?source=tweet\" data-url=\"https://seekingalpha.com/news/659261\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659181\" data-ts=\"1352745836\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHN\" target=\"_blank\">ACHN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659181\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shares of Achillion (ACHN -11%) drop hard on the back of competitor Gilead&#39;s (GILD +12%)...</a></h4>Shares of Achillion (<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a> <font color=\"red\">-11%</font>) drop hard on the back of competitor Gilead's (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color=\"green\">+12%</font>) <a target=\"_blank\" href=\"https://seekingalpha.com/market_currents/post/658511\">positive results</a> from Phase 2 testing of its Hep C antiviral drug ribavirin.  <a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a> is developing its own hepatitis C virus treatment which has performed well in tests. Wells Fargo's Brian Abraham says <a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a> is \"<a target=\"_blank\" href=\"http://www.streetinsider.com/Analyst+Comments/Achillion+Pharmaceuticals+%28ACHN%29+Weakness+is+a+Buying+Chance+-+Analyst/7866298.html\">well-positioned</a>\" to participate in the HCV market, and today's weakness creates a buying opportunity.<div class=\"tiny-share-widget\" data-id=\"659181\" data-linked=\"Shares of Achillion (ACHN -11%) drop hard on the back of competitor Gilead&#39;s (GILD +12%)...\" data-tweet=\"$ACHN $ACHN $GILD - Shares of Achillion (ACHN -11%) drop hard on the back of competitor Gilead&#39;s (GILD +12%) positive results from Phase 2 testing of its Hep C antiviral drug ribavirin. ACHN is developing its own hepatitis C virus treatment which has pe... https://seekingalpha.com/news/659181?source=tweet\" data-url=\"https://seekingalpha.com/news/659181\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659141\" data-ts=\"1352744008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659141\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Another head-scratching move by J.C. Penney (JCP -10.2%): CEO Ron Johnson tells USA Today the...</a></h4><p>Another head-scratching move by J.C. Penney (<a href=\"https://seekingalpha.com/symbol/JCP\" title=\"J.C. Penney Company Inc.\">JCP</a> <font color=\"red\">-10.2%</font>): CEO Ron Johnson tells USA Today the retailer will <a target=\"_blank\" href=\"http://www.usatoday.com/story/money/business/2012/11/11/jcpenney-holiday-strategy/1684411/\">hand out</a> millions of buttons - instead of coupons - this holiday season with a code on the back that leads to prizes for some shoppers at its website. Though increasing online traffic is a priority after the embattled retailer saw Internet sales plunge 37% Y/Y in Q3, analysts warn department store shoppers need the simplicity and cold comfort of coupons and sales over the painful learning curve of riding shotgun with the JCP transformation. JCP hit a 52-week low of $18.25 earlier before trickling back higher.</p><div class=\"tiny-share-widget\" data-id=\"659141\" data-linked=\"Another head-scratching move by J.C. Penney (JCP -10.2%): CEO Ron Johnson tells USA Today the...\" data-tweet=\"$JCP - Another head-scratching move by J.C. Penney (JCP -10.2%): CEO Ron Johnson tells USA Today the retailer will hand out millions of buttons - instead of coupons - this holiday season with a code on the back that leads to prizes for some shoppers at ... https://seekingalpha.com/news/659141?source=tweet\" data-url=\"https://seekingalpha.com/news/659141\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659131\" data-ts=\"1352743945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ET-OLD\" target=\"_blank\">ET-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659131\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ExactTarget (ET-OLD -11.4%) has fallen to new post-IPO lows today. Shares barely moved on Friday...</a></h4>ExactTarget (<a href='https://seekingalpha.com/symbol/ET-OLD' title='Energy Transfer LP'>ET-OLD</a> <font color='red'>-11.4%</font>) has fallen to new post-IPO lows today. Shares barely moved on Friday after the company delivered a <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/654431\">Q3 beat</a>, but it's worth noting online marketing software peers Responsys (<a href='https://seekingalpha.com/symbol/MKTG' title='Responsys'>MKTG</a> <font color='red'>-3%</font>) and Constant Contact (<a href='https://seekingalpha.com/symbol/CTCT' title='Constant Contact, Inc.'>CTCT</a> <font color='green'>+2.5%</font>) were hammered (<a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/644061\">I</a>, <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/617201\">II</a>) following their own Q3 reports, and that ExactTarget fell in sympathy each time.<div class=\"tiny-share-widget\" data-id=\"659131\" data-linked=\"ExactTarget (ET-OLD -11.4%) has fallen to new post-IPO lows today. Shares barely moved on Friday...\" data-tweet=\"$ET-OLD $ET-OLD $MKTG - ExactTarget (ET-OLD -11.4%) has fallen to new post-IPO lows today. Shares barely moved on Friday after the company delivered a Q3 beat, but it&#39;s worth noting online marketing software peers Responsys (MKTG -3%) and Constant Conta... https://seekingalpha.com/news/659131?source=tweet\" data-url=\"https://seekingalpha.com/news/659131\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659101\" data-ts=\"1352743129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDD\" target=\"_blank\">DDD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659101\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3D Systems (DDD -7.2%) is off sharply after SA&#39;s Douglas W. House provides a critical analysis...</a></h4><p>3D Systems (<a href=\"https://seekingalpha.com/symbol/DDD\" title=\"3D Systems Corp.\">DDD</a> <font color=\"red\">-7.2%</font>) is off sharply after SA's Douglas W. House provides a <a target=\"_blank\" href=\"https://seekingalpha.com/article/999501-3d-systems-has-the-printer-jammed\">critical analysis</a> of the company's financials, as provided in 3D's <a target=\"_blank\" href=\"http://sec.gov/Archives/edgar/data/910638/000119312512434608/d426213d10q.htm\">Q3 10-Q</a>. Like <a target=\"_blank\" href=\"https://seekingalpha.com/article/943201-3d-systems-at-the-peak-of-inflated-expectations\">Gray Wolf Research</a>, House thinks 3D's growth has been overstated thanks to an acquisition spree, and believes management hasn't been forthright about giving details on how acquisitions have performed. He also argues the market for industrial 3D printers has matured, and expects sales of 3D's inexpensive Cube printer to disappoint. <a href=\"https://seekingalpha.com/symbol/SSYS\" title=\"Stratasys, Inc.\">SSYS</a> <font color=\"red\">-1.3%</font>.</p><div class=\"tiny-share-widget\" data-id=\"659101\" data-linked=\"3D Systems (DDD -7.2%) is off sharply after SA&#39;s Douglas W. House provides a critical analysis...\" data-tweet=\"$DDD $DDD $SSYS - 3D Systems (DDD -7.2%) is off sharply after SA&#39;s Douglas W. House provides a critical analysis of the company&#39;s financials, as provided in 3D&#39;s Q3 10-Q. Like Gray Wolf Research, House thinks 3D&#39;s growth has been overstated thanks to an... https://seekingalpha.com/news/659101?source=tweet\" data-url=\"https://seekingalpha.com/news/659101\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659091\" data-ts=\"1352742934\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659091\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors have expressed interest in U.S. Steel&#39;s (X +2.2%) Slovak operation because of its...</a></h4><p>Investors have <a target=\"_blank\" href=\"http://www.reuters.com/article/2012/11/12/ussteel-slovakia-idUSL5E8MCBKV20121112\">expressed interest</a> in U.S. Steel's (<a href=\"https://seekingalpha.com/symbol/X\" title=\"United States Steel Corporation\">X</a> <font color=\"green\">+2.2%</font>) Slovak operation because of its location, low labor costs and product portfolio, Reuters reports. Steelmaking conglomerate Thyssen, in the throes of a radical restructuring in which it is trying to sell assets to slash debt and refocus on its core European business, denies interest.</p><div class=\"tiny-share-widget\" data-id=\"659091\" data-linked=\"Investors have expressed interest in U.S. Steel&#39;s (X +2.2%) Slovak operation because of its...\" data-tweet=\"$X - Investors have expressed interest in U.S. Steel&#39;s (X +2.2%) Slovak operation because of its location, low labor costs and product portfolio, Reuters reports. Steelmaking conglomerate Thyssen, in the throes of a radical restructuring in which it is ... https://seekingalpha.com/news/659091?source=tweet\" data-url=\"https://seekingalpha.com/news/659091\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"659041\" data-ts=\"1352742169\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYNO\" target=\"_blank\">CYNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/659041\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cynosure (CYNO -5.6%) is lower today after announcing a 2.6M share secondary offering. El.En....</a></h4><p>Cynosure (<a href=\"https://seekingalpha.com/symbol/CYNO\" title=\"Cynosure, Inc.\">CYNO</a> <font color=\"red\">-5.6%</font>) is lower today after announcing a 2.6M share secondary offering. El.En. S.p.A. is also offering an additional 600K shares. The company intends to use the net proceeds of its portion of the sale to fund the potential acquisition of targeted products, technologies or businesses. It will not receive any proceeds from the sale of the shares by El.En. S.p.A.</p><div class=\"tiny-share-widget\" data-id=\"659041\" data-linked=\"Cynosure (CYNO -5.6%) is lower today after announcing a 2.6M share secondary offering. El.En....\" data-tweet=\"$CYNO - Cynosure (CYNO -5.6%) is lower today after announcing a 2.6M share secondary offering. El.En. S.p.A. is also offering an additional 600K shares. The company intends to use the net proceeds of its portion of the sale to fund the potential acquisi... https://seekingalpha.com/news/659041?source=tweet\" data-url=\"https://seekingalpha.com/news/659041\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658991\" data-ts=\"1352741493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRPN\" target=\"_blank\">GRPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658991\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Groupon (GRPN -3.8%) is bleeding again today after William Blair downgrades shares to Market...</a></h4><p>Groupon (<a href=\"https://seekingalpha.com/symbol/GRPN\" title=\"Groupon, Inc.\">GRPN</a> <font color=\"red\">-3.8%</font>) is bleeding again today after William Blair downgrades shares to Market Perform in response to the company's poor Q3 report - Groupon now has a market cap of just $1.7B. Also, <a target=\"_blank\" href=\"http://www.reuters.com/article/2012/11/12/us-groupon-dailydeals-idUSBRE8AB05120121112?feedType=RSS&amp;feedName=businessNews&amp;utm_source=dlvr.it&amp;utm_medium=twitter&amp;dlvrit=56943\">Reuters</a> just took aim at Groupon, noting (among other things) a Raymond James survey in which 39% of merchants who used daily deals services said they don't plan to run another Groupon promotion, due to high commissions and low repeat customer rates. (Groupon Q3: <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/653631\">I</a>, <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/653921\">II</a>, <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/654611\">III</a>)</p><div class=\"tiny-share-widget\" data-id=\"658991\" data-linked=\"Groupon (GRPN -3.8%) is bleeding again today after William Blair downgrades shares to Market...\" data-tweet=\"$GRPN - Groupon (GRPN -3.8%) is bleeding again today after William Blair downgrades shares to Market Perform in response to the company&#39;s poor Q3 report - Groupon now has a market cap of just $1.7B. Also, Reuters just took aim at Groupon, noting (among ... https://seekingalpha.com/news/658991?source=tweet\" data-url=\"https://seekingalpha.com/news/658991\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658971\" data-ts=\"1352741220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAV\" target=\"_blank\">NAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658971\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navistar (NAV +1.9%) trades up after Baird raised its rating on the shares this morning to...</a></h4><p>Navistar (<a href=\"https://seekingalpha.com/symbol/NAV\" title=\"Navistar International Corporation\">NAV</a> <font color=\"green\">+1.9%</font>) trades up after Baird <a target=\"_blank\" href=\"http://www.streetinsider.com/Upgrades/Baird+Upgrades+Navistar+International+%28NAV%29+to+Outperform/7865060.html\">raised its rating</a> on the shares this morning to Outperform on relative valuation, citing optimism over its earnings picture and potential upside catalysts from recent strategic initiatives that will potentially give a boost to its bottom line. The firm also raises its price target to $30 from $20.</p><div class=\"tiny-share-widget\" data-id=\"658971\" data-linked=\"Navistar (NAV +1.9%) trades up after Baird raised its rating on the shares this morning to...\" data-tweet=\"$NAV - Navistar (NAV +1.9%) trades up after Baird raised its rating on the shares this morning to Outperform on relative valuation, citing optimism over its earnings picture and potential upside catalysts from recent strategic initiatives that will pote... https://seekingalpha.com/news/658971?source=tweet\" data-url=\"https://seekingalpha.com/news/658971\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658931\" data-ts=\"1352740424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRMN\" target=\"_blank\">GRMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658931\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Garmin (GRMN -2.1%) is lower thanks to a downgrade to Sell from Goldman&#39;s Simona Jankowski,...</a></h4><p>Garmin (<a href=\"https://seekingalpha.com/symbol/GRMN\" title=\"Garmin Ltd.\">GRMN</a> <font color=\"red\">-2.1%</font>) is lower thanks to a <a target=\"_blank\" href=\"http://www.forbes.com/sites/ericsavitz/2012/11/12/garmin-goldman-downgrades-to-sell-target-price-now-34/\">downgrade to Sell</a> from Goldman's Simona Jankowski, who's worried about the ongoing cannibalization of PNDs by smartphones, and growing competition in the fitness GPS market. Jankowski's Q4 and Q1 EPS forecasts are respective 3% and 10% below <a target=\"_blank\" href=\"http://finance.yahoo.com/q/ae?s=GRMN+Analyst+Estimates\">consensus</a>. Apple's inclusion of turn-by-turn navigation in iOS 6 (enabled by Tom-Tom) could accelerate the smartphone cannibalization trend. Garmin's auto/mobile PND sales were <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/625601\">flat Y/Y in Q3</a>.</p><div class=\"tiny-share-widget\" data-id=\"658931\" data-linked=\"Garmin (GRMN -2.1%) is lower thanks to a downgrade to Sell from Goldman&#39;s Simona Jankowski,...\" data-tweet=\"$GRMN - Garmin (GRMN -2.1%) is lower thanks to a downgrade to Sell from Goldman&#39;s Simona Jankowski, who&#39;s worried about the ongoing cannibalization of PNDs by smartphones, and growing competition in the fitness GPS market. Jankowski&#39;s Q4 and Q1 EPS fore... https://seekingalpha.com/news/658931?source=tweet\" data-url=\"https://seekingalpha.com/news/658931\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658871\" data-ts=\"1352739481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DSCI\" target=\"_blank\">DSCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658871\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Derma Sciences (DSCI +2.6%) moves up after it&#39;s Q3 beats across the board on narrower losses....</a></h4><p>Derma Sciences (<a href=\"https://seekingalpha.com/symbol/DSCI\" title=\"Derma Sciences Inc.\">DSCI</a> <font color=\"green\">+2.6%</font>) moves up after it's <a target=\"_blank\" href=\"https://seekingalpha.com/market_currents/post/658041\">Q3 beats</a> across the board on narrower losses. Total revenue jumped 24% Y/Y on a 67% increase in sales of its advanced wound care products and a 9% gain in traditional wound care. Better cost controls gave gross margins a big boost, gaining 5 percentage points to 35.2% from 30.0% during the prior-year period.</p><div class=\"tiny-share-widget\" data-id=\"658871\" data-linked=\"Derma Sciences (DSCI +2.6%) moves up after it&#39;s Q3 beats across the board on narrower losses....\" data-tweet=\"$DSCI - Derma Sciences (DSCI +2.6%) moves up after it&#39;s Q3 beats across the board on narrower losses. Total revenue jumped 24% Y/Y on a 67% increase in sales of its advanced wound care products and a 9% gain in traditional wound care. Better cost contro... https://seekingalpha.com/news/658871?source=tweet\" data-url=\"https://seekingalpha.com/news/658871\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658761\" data-ts=\"1352737196\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRQ\" target=\"_blank\">DRQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658761\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dril-Quip (DRQ +3%) is upgraded to Buy from Neutral by Global Hunter, which believes negative...</a></h4>Dril-Quip (<a href='https://seekingalpha.com/symbol/DRQ' title='Dril-Quip, Inc.'>DRQ</a> <font color=\"green\">+3%</font>) is <a target=\"_blank\" href=\"http://www.streetinsider.com/Upgrades/UPDATE%3A+Global+Hunter+Securities+Upgrades+Dril-Quip+%28DRQ%29+to+Buy%2C+Orders+to+Set+New+Records+in+Coming+Qtrs/7865163.html\" target=\"_blank\">upgraded</a> to Buy from Neutral by Global Hunter, which believes negative news is out of the way. While <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/655271\">Q3 margins</a> were weaker than expected and Q4 guidance was flat, the firm says orders are likely to set new records over the coming  quarters; it believes a healthy backlog will turn into higher revenues and record earnings on industry leading margins.<div class=\"tiny-share-widget\" data-id=\"658761\" data-linked=\"Dril-Quip (DRQ +3%) is upgraded to Buy from Neutral by Global Hunter, which believes negative...\" data-tweet=\"$DRQ - Dril-Quip (DRQ +3%) is upgraded to Buy from Neutral by Global Hunter, which believes negative news is out of the way. While Q3 margins were weaker than expected and Q4 guidance was flat, the firm says orders are likely to set new records over the... https://seekingalpha.com/news/658761?source=tweet\" data-url=\"https://seekingalpha.com/news/658761\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658751\" data-ts=\"1352736682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCOM\" target=\"_blank\">JCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658751\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J2 Global (JCOM +2.7%) has acquired Ziff Davis, owner of PCMag.com, ExtremeTech, Geek.com, and...</a></h4><p>J2 Global (<a href=\"https://seekingalpha.com/symbol/JCOM\" title=\"j2 Global, Inc.\">JCOM</a> <font color=\"green\">+2.7%</font>) has acquired Ziff Davis, owner of PCMag.com, ExtremeTech, Geek.com, and other tech-oriented Web properties, for $167M in cash. The purchase is slightly off the beaten path for J2, a provider of hosted communications services, but the company notes it's both a major buyer of ads, and a seller via ad-supported sites such as eFax Free. Buying Ziff-Davis puts J2 into competition with GeekNet (<a href=\"https://seekingalpha.com/symbol/GKNT\" title=\"Geeknet, Inc.\">GKNT</a> <font color=\"red\">-1.5%</font>). J2 recently <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/643591\">made an offer</a> to buy cloud backup services firm Carbonite.</p><div class=\"tiny-share-widget\" data-id=\"658751\" data-linked=\"J2 Global (JCOM +2.7%) has acquired Ziff Davis, owner of PCMag.com, ExtremeTech, Geek.com, and...\" data-tweet=\"$JCOM $JCOM $GKNT - J2 Global (JCOM +2.7%) has acquired Ziff Davis, owner of PCMag.com, ExtremeTech, Geek.com, and other tech-oriented Web properties, for $167M in cash. The purchase is slightly off the beaten path for J2, a provider of hosted communica... https://seekingalpha.com/news/658751?source=tweet\" data-url=\"https://seekingalpha.com/news/658751\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658681\" data-ts=\"1352735535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABMD\" target=\"_blank\">ABMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658681\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abiomed (ABMD +2%) says it&#39;s received an FDA Investigational Device Exemption approval for...</a></h4><p>Abiomed (<a href=\"https://seekingalpha.com/symbol/ABMD\" title=\"ABIOMED, Inc.\">ABMD</a> <font color=\"green\">+2%</font>) says it's received an FDA Investigational Device Exemption approval for clinical studies of its new Impella RP percutaneous heart pump. The study is expected to begin in early 2013 and will enroll 30 patients with signs of right side heart failure requiring hemodynamic support, and are being treated in a catheterization lab or cardiac surgery suite.</p><div class=\"tiny-share-widget\" data-id=\"658681\" data-linked=\"Abiomed (ABMD +2%) says it&#39;s received an FDA Investigational Device Exemption approval for...\" data-tweet=\"$ABMD - Abiomed (ABMD +2%) says it&#39;s received an FDA Investigational Device Exemption approval for clinical studies of its new Impella RP percutaneous heart pump. The study is expected to begin in early 2013 and will enroll 30 patients with signs of rig... https://seekingalpha.com/news/658681?source=tweet\" data-url=\"https://seekingalpha.com/news/658681\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658611\" data-ts=\"1352733525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCPIQ\" target=\"_blank\">MCPIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658611\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After slumping 13% Friday on disclosure of a SEC investigation, Molycorp (MCP -9%) continues...</a></h4><p>After slumping 13% Friday on disclosure of a <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/656261\">SEC investigation</a>, Molycorp (MCP <font color=\"red\">-9%</font>) continues lower today. Dahlman Rose also notes MCP <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/654541\">reported</a> a $150M increase in capital expenditures; the firm sees 2013 as a <a target=\"_blank\" href=\"http://www.briefing.com/GeneralContent/InPlayEQ/Active/TickerSearch/TickerSearchInPlayEq.aspx?SearchTextBox=mcp&amp;SearchType=Ticker&amp;x=21&amp;y=11&amp;PagePrefix=EQInPlayPage\">transitional year</a>, where cash management and project execution will be crucial in unlocking the value of Mountain Pass without the need for additional capital.</p><div class=\"tiny-share-widget\" data-id=\"658611\" data-linked=\"After slumping 13% Friday on disclosure of a SEC investigation, Molycorp (MCP -9%) continues...\" data-tweet=\"$MCPIQ - After slumping 13% Friday on disclosure of a SEC investigation, Molycorp (MCP -9%) continues lower today. Dahlman Rose also notes MCP reported a $150M increase in capital expenditures; the firm sees 2013 as a transitional year, where cash manag... https://seekingalpha.com/news/658611?source=tweet\" data-url=\"https://seekingalpha.com/news/658611\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658511\" data-ts=\"1352731746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658511\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gilead (NASDAQ:GILD) +11.3% after saying over the weekend that a combination of its hepatitis C...</a></h4><p>Gilead (NASDAQ:<a href=\"https://seekingalpha.com/symbol/GILD\" title=\"Gilead Sciences, Inc.\">GILD</a>) <font color=\"green\">+11.3%</font> after saying over the weekend that a combination of its hepatitis C therapies sofosbuvir and GS-5885, along with the antiviral drug ribavirin, <a target=\"_blank\" href=\"http://www.businessweek.com/news/2012-11-12/gilead-climbs-on-study-results-of-hepatitis-c-combo\">cleared the virus</a> in all 25 patients in a Phase II study. \"This is starting to look like a home-run,\" says RBC analyst Michael Yee. Gilead's excellent results add to <a target=\"_blank\" href=\"https://seekingalpha.com/currents/search?query=hepatitis\">very good</a> Phase II data from Merck and Abbott Labs. (PR)</p><div class=\"tiny-share-widget\" data-id=\"658511\" data-linked=\"Gilead (NASDAQ:GILD) +11.3% after saying over the weekend that a combination of its hepatitis C...\" data-tweet=\"$GILD - Gilead (NASDAQ:GILD) +11.3% after saying over the weekend that a combination of its hepatitis C therapies sofosbuvir and GS-5885, along with the antiviral drug ribavirin, cleared the virus in all 25 patients in a Phase II study. &quot;This is startin... https://seekingalpha.com/news/658511?source=tweet\" data-url=\"https://seekingalpha.com/news/658511\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658491\" data-ts=\"1352731492\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRIP\" target=\"_blank\">TRIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658491\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TripAdvisor (TRIP +3.9%) opens higher after receiving a two-notch upgrade to Overweight from...</a></h4><p>TripAdvisor (<a href=\"https://seekingalpha.com/symbol/TRIP\" title=\"TripAdvisor Inc.\">TRIP</a> <font color=\"green\">+3.9%</font>) opens higher after receiving a two-notch <a target=\"_blank\" href=\"http://www.forbes.com/sites/ericsavitz/2012/11/12/tripadvisor-morgan-stanley-turns-bullish-sets-41-target/?utm_source=twitterfeed&amp;utm_medium=twitter\">upgrade to Overweight </a>from Morgan Stanley's Scott DeVitt, who's enthusiastic about a new monetization strategy focused on a <a target=\"_blank\" href=\"http://en.wikipedia.org/wiki/Metasearch_engine\">metasearch engine</a> (kind of like Kayak) rather than pop-up windows. DeVitt also points out Q3 hotel shopper growth was a solid 30% Y/Y, forecasts a 17% CAGR for the company over the next 4 years, and thinks the <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/653751\">steep price</a> paid by Priceline for Kayak demonstrates TripAdvisor's value.</p><div class=\"tiny-share-widget\" data-id=\"658491\" data-linked=\"TripAdvisor (TRIP +3.9%) opens higher after receiving a two-notch upgrade to Overweight from...\" data-tweet=\"$TRIP - TripAdvisor (TRIP +3.9%) opens higher after receiving a two-notch upgrade to Overweight from Morgan Stanley&#39;s Scott DeVitt, who&#39;s enthusiastic about a new monetization strategy focused on a metasearch engine (kind of like Kayak) rather than pop-... https://seekingalpha.com/news/658491?source=tweet\" data-url=\"https://seekingalpha.com/news/658491\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658481\" data-ts=\"1352731378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658481\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.C. Penney (JCP -3.1%) trades lower as more late-to-the-party analyst downgrades pour in and...</a></h4>J.C. Penney (<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a> <font color='red'>-3.1%</font>) trades lower as more <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/657921\">late-to-the-party analyst downgrades</a> pour in and <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/657921\">fresh calls</a> for Ron Johnson's firing are heard. Questions on the retailer's <a target=\"_blank\" href=\"https://twitter.com/BrianSozzi/status/267994597521752065\">financial viability</a> in the face of same-store sales falling off +20% for three straight quarters are also being posed by more people than just gleeful JCP shorts.<div class=\"tiny-share-widget\" data-id=\"658481\" data-linked=\"J.C. Penney (JCP -3.1%) trades lower as more late-to-the-party analyst downgrades pour in and...\" data-tweet=\"$JCP - J.C. Penney (JCP -3.1%) trades lower as more late-to-the-party analyst downgrades pour in and fresh calls for Ron Johnson&#39;s firing are heard. Questions on the retailer&#39;s financial viability in the face of same-store sales falling off +20% for thr... https://seekingalpha.com/news/658481?source=tweet\" data-url=\"https://seekingalpha.com/news/658481\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658471\" data-ts=\"1352731324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIM\" target=\"_blank\">CIM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658471\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chimera Investment (CIM +6.3%) opens higher as Annaly (NYSE:NLY) bids for CreXus and says it...</a></h4>Chimera Investment (<a href='https://seekingalpha.com/symbol/CIM' title='Chimera Investment Corporation'>CIM</a><font color=\"green\"> +6.3%</font>) opens higher as Annaly (NYSE:<a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a>) bids for CreXus and says it will <a target=\"_blank\" target=\"_blank\" href=\"https://seekingalpha.com/currents/post/657941\">seek to allocate</a> up to 25% of its capital outside of the Agency REIT sector. Like CreXus, Chimera resides in <a target=\"_blank\" target=\"_blank\" href=\"http://www.annaly.com/site/annalyfamilyofcompanies.aspx\">Annaly's family tree</a> and - with a focus on non-Agency paper - coud be the next target.<div class=\"tiny-share-widget\" data-id=\"658471\" data-linked=\"Chimera Investment (CIM +6.3%) opens higher as Annaly (NYSE:NLY) bids for CreXus and says it...\" data-tweet=\"$CIM $CIM $NLY - Chimera Investment (CIM +6.3%) opens higher as Annaly (NYSE:NLY) bids for CreXus and says it will seek to allocate up to 25% of its capital outside of the Agency REIT sector. Like CreXus, Chimera resides in Annaly&#39;s family tree and - wi... https://seekingalpha.com/news/658471?source=tweet\" data-url=\"https://seekingalpha.com/news/658471\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658461\" data-ts=\"1352730864\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHW\" target=\"_blank\">SHW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658461\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Sherwin-Williams&#39; (NYSE:SHW) acquisition of Comex: &quot;This transaction will significantly...</a></h4><p>More on Sherwin-Williams' (NYSE:<a href=\"https://seekingalpha.com/symbol/SHW\" title=\"The Sherwin-Williams Company\">SHW</a>) <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/658401\">acquisition</a> of Comex: \"This transaction will significantly increase our presence in markets where our store count is low, (and) it builds upon our strategy to grow our architectural paint business in the Americas,\" says SHW CEO Christopher Connor. Comex operates in Latin America, the U.S. and Canada, and generated 2011 sales of $1.4B. SHW <font color=\"green\">+5.4%</font>.</p><div class=\"tiny-share-widget\" data-id=\"658461\" data-linked=\"More on Sherwin-Williams&#39; (NYSE:SHW) acquisition of Comex: &quot;This transaction will significantly...\" data-tweet=\"$SHW - More on Sherwin-Williams&#39; (NYSE:SHW) acquisition of Comex: &quot;This transaction will significantly increase our presence in markets where our store count is low, (and) it builds upon our strategy to grow our architectural paint business in the Ameri... https://seekingalpha.com/news/658461?source=tweet\" data-url=\"https://seekingalpha.com/news/658461\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658361\" data-ts=\"1352729716\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658361\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Market preview: Stock futures are higher and EU shares are mostly in the green as investors...</a></h4><b>Market preview:</b> Stock futures are higher and EU shares are mostly in the green as investors focus on China's <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/657391\">increasing exports</a> rather than Japan's expected slide <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/657671\">back into recession</a>. The Greek parliament's <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/657661\">passing</a> of the 2013 budget is also apparently providing cheer despite the eurozone's unwillingness to release the latest tranche of the country's bailout. The S&amp;P benchmark is <font color=\"green\">+0.3%</font>. Jeffries <font color=\"green\">soars 22.5%</font> on news it's <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/658011\">being acquired</a>.<div class=\"tiny-share-widget\" data-id=\"658361\" data-linked=\"Market preview: Stock futures are higher and EU shares are mostly in the green as investors...\" data-tweet=\"Market preview: Stock futures are higher and EU shares are mostly in the green as investors focus on China&#39;s increasing exports rather than Japan&#39;s expected slide back into recession. The Greek parliament&#39;s passing of the 2013 budget is also apparently ... https://seekingalpha.com/news/658361?source=tweet\" data-url=\"https://seekingalpha.com/news/658361\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658411\" data-ts=\"1352729433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCP\" target=\"_blank\">PCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658411\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket gainers: TIE +43%. JEF +24%. OTC:MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%....</a></h4><b>Premarket gainers:</b> TIE <font color=\"green\">+43%</font>. <a href=\"https://seekingalpha.com/symbol/JEF\" title=\"Jefferies Group Inc.\">JEF</a> <font color=\"green\">+24%</font>. <a href=\"https://seekingalpha.com/symbol/MYRX\" title=\"Myrexis, Inc.\">OTC:MYRX</a> <font color=\"green\">+17%</font>. <a href=\"https://seekingalpha.com/symbol/CXS\" title=\"CreXus Investment Corporation\">CXS</a> <font color=\"green\">+15%</font>. <a href=\"https://seekingalpha.com/symbol/GILD\" title=\"Gilead Sciences, Inc.\">GILD</a> <font color=\"green\">+12%</font>. <a href=\"https://seekingalpha.com/symbol/CELG\" title=\"Celgene Corporation\">CELG</a> <font color=\"green\">+10%</font>. <a href=\"https://seekingalpha.com/symbol/SVNT\" title=\"Seventy Seven Energy Inc. New\">SVNT</a> <font color=\"green\">+7%</font>. <a href=\"https://seekingalpha.com/symbol/SQNM\" title=\"Sequenom, Inc.\">SQNM</a> <font color=\"green\">+7%</font>. <a href=\"https://seekingalpha.com/symbol/LUK-OLD\" title=\"Leucadia National Corporation\">LUK-OLD</a> <font color=\"green\">+7%</font>. RIMM <font color=\"green\">+6%</font>. <a href=\"https://seekingalpha.com/symbol/NKTR\" title=\"Nektar Therapeutics\">NKTR</a> <font color=\"green\">+6%</font>. STV <font color=\"green\">+5%</font>. <a href=\"https://seekingalpha.com/symbol/DNDN\" title=\"Dendreon Corporation\">DNDN</a> <font color=\"green\">+5%</font>. <a href=\"https://seekingalpha.com/symbol/CEL\" title=\"Cellcom Israel, Ltd.\">CEL</a> <font color=\"green\">+5%</font>. <a href=\"https://seekingalpha.com/symbol/PCP\" title=\"Precision Castparts Corp.\">PCP</a> <font color=\"green\">+5%</font>.  <br><b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/CLVS\" title=\"Clovis Oncology\">CLVS</a> <font color=\"red\">-41%</font>. STSI <font color=\"red\">-20%</font>. NBG <font color=\"red\">-11%</font>.<div class=\"tiny-share-widget\" data-id=\"658411\" data-linked=\"Premarket gainers: TIE +43%. JEF +24%. OTC:MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%....\" data-tweet=\"$PCP $PCP $LUK-OLD - Premarket gainers: TIE +43%. JEF +24%. OTC:MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%. SQNM +7%. LUK-OLD +7%. RIMM +6%. NKTR +6%. STV +5%. DNDN +5%. CEL +5%. PCP +5%. Losers: CLVS -41%. STSI -20%. NBG -11%. https://seekingalpha.com/news/658411?source=tweet\" data-url=\"https://seekingalpha.com/news/658411\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658321\" data-ts=\"1352729164\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDCC\" target=\"_blank\">IDCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658321\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InterDigital (NASDAQ:IDCC) +3.9% after establishing Q4 revenue guidance of $62M-$64M, above a...</a></h4><p>InterDigital (NASDAQ:<a href=\"https://seekingalpha.com/symbol/IDCC\" title=\"InterDigital, Inc.\">IDCC</a>) <font color=\"green\">+3.9%</font> after establishing Q4 revenue guidance of $62M-$64M, above a consensus of $58.7M. InterDigital, which posted <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/608371\">Q3 results</a> and announced a <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/604991\">big restructuring</a> last month, attributes the healthy guidance to strong phone volumes from Japanese licensees. (PR)</p><div class=\"tiny-share-widget\" data-id=\"658321\" data-linked=\"InterDigital (NASDAQ:IDCC) +3.9% after establishing Q4 revenue guidance of $62M-$64M, above a...\" data-tweet=\"$IDCC - InterDigital (NASDAQ:IDCC) +3.9% after establishing Q4 revenue guidance of $62M-$64M, above a consensus of $58.7M. InterDigital, which posted Q3 results and announced a big restructuring last month, attributes the healthy guidance to strong phon... https://seekingalpha.com/news/658321?source=tweet\" data-url=\"https://seekingalpha.com/news/658321\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658301\" data-ts=\"1352728877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SODA\" target=\"_blank\">SODA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658301\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SodaStream (NASDAQ:SODA) announces a deal with Campbell Soup (NYSE:CPB) to license Campbell&#39;s V8...</a></h4><p>SodaStream (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SODA\" title=\"SodaStream International\">SODA</a>) <a target=\"_blank\" href=\"http://www.businesswire.com/news/home/20121112005864/en/Campbell-Soup-Company-SodaStream-Offer-V8-Splash\">announces a deal</a> with Campbell Soup (NYSE:<a href=\"https://seekingalpha.com/symbol/CPB\" title=\"Campbell Soup Company\">CPB</a>) to license Campbell's V8 Splash and V8 V-Fusion brands for its home beverage system. Shares of SODA <font color=\"green\">+1.9%</font> premarket.</p><div class=\"tiny-share-widget\" data-id=\"658301\" data-linked=\"SodaStream (NASDAQ:SODA) announces a deal with Campbell Soup (NYSE:CPB) to license Campbell&#39;s V8...\" data-tweet=\"$SODA $SODA $CPB - SodaStream (NASDAQ:SODA) announces a deal with Campbell Soup (NYSE:CPB) to license Campbell&#39;s V8 Splash and V8 V-Fusion brands for its home beverage system. Shares of SODA +1.9% premarket. https://seekingalpha.com/news/658301?source=tweet\" data-url=\"https://seekingalpha.com/news/658301\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658241\" data-ts=\"1352727972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCP\" target=\"_blank\">PCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658241\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Titanium Metals (TIE) +43% premarket on Friday&#39;s news that it agreed to be acquired by Precision...</a></h4><p>Titanium Metals (TIE) <font color=\"green\">+43%</font> premarket on Friday's news that it <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/657031\">agreed to be acquired</a> by Precision Castparts (NYSE:<a href=\"https://seekingalpha.com/symbol/PCP\" title=\"Precision Castparts Corp.\">PCP</a>) for $16.50/share, a 43% premium to the metal products company's Friday closing price. Since PCP was TIE's biggest customer, <a target=\"_blank\" href=\"http://www.reuters.com/article/2012/11/10/precisioncastparts-titaniummetals-idUSL3E8M98LL20121110\">cost reductions</a> from the deal should be significant, analysts say, and PCP has shown an ability to integrate acquisitions smoothly. PCP <font color=\"green\">+4.2%</font>.</p><div class=\"tiny-share-widget\" data-id=\"658241\" data-linked=\"Titanium Metals (TIE) +43% premarket on Friday&#39;s news that it agreed to be acquired by Precision...\" data-tweet=\"$PCP - Titanium Metals (TIE) +43% premarket on Friday&#39;s news that it agreed to be acquired by Precision Castparts (NYSE:PCP) for $16.50/share, a 43% premium to the metal products company&#39;s Friday closing price. Since PCP was TIE&#39;s biggest customer, cost... https://seekingalpha.com/news/658241?source=tweet\" data-url=\"https://seekingalpha.com/news/658241\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658231\" data-ts=\"1352727885\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CELG\" target=\"_blank\">CELG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658231\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">In contrast to Clovis&#39; share-price collapse, Celgene (NASDAQ:CELG) is +8.6% after saying on...</a></h4><p>In contrast to Clovis' <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/658211\">share-price collapse</a>, Celgene (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CELG\" title=\"Celgene Corporation\">CELG</a>) is <font color=\"green\">+8.6%</font> after saying on Friday that its Abraxane treatment for advanced pancreatic cancer <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/657211\">lengthened the survival</a> of patients in a Phase III study. Pancreatic cancer could add <a target=\"_blank\" href=\"http://www.thestreet.com/story/11763237/1/celgene-abraxane-boosts-pancreatic-cancer-survival.html\">up to $1B</a> in sales of Abraxane, which is already approved to treat breast and lung tumors.</p><div class=\"tiny-share-widget\" data-id=\"658231\" data-linked=\"In contrast to Clovis&#39; share-price collapse, Celgene (NASDAQ:CELG) is +8.6% after saying on...\" data-tweet=\"$CELG - In contrast to Clovis&#39; share-price collapse, Celgene (NASDAQ:CELG) is +8.6% after saying on Friday that its Abraxane treatment for advanced pancreatic cancer lengthened the survival of patients in a Phase III study. Pancreatic cancer could add u... https://seekingalpha.com/news/658231?source=tweet\" data-url=\"https://seekingalpha.com/news/658231\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658211\" data-ts=\"1352727582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658211\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clovis Oncology (NASDAQ:CLVS) shares collapse 42% after its CO-101 treatment failed to prolong...</a></h4><p>Clovis Oncology (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CLVS\" title=\"Clovis Oncology\">CLVS</a>) shares <font color=\"red\">collapse 42%</font> after its CO-101 treatment failed to prolong the survival of patients with pancreatic cancer vs gemcitabine in a phase III study. Clovis is now ending the development of the drug  pending further evaluation of the trial data.</p><div class=\"tiny-share-widget\" data-id=\"658211\" data-linked=\"Clovis Oncology (NASDAQ:CLVS) shares collapse 42% after its CO-101 treatment failed to prolong...\" data-tweet=\"$CLVS - Clovis Oncology (NASDAQ:CLVS) shares collapse 42% after its CO-101 treatment failed to prolong the survival of patients with pancreatic cancer vs gemcitabine in a phase III study. Clovis is now ending the development of the drug pending further ... https://seekingalpha.com/news/658211?source=tweet\" data-url=\"https://seekingalpha.com/news/658211\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658161\" data-ts=\"1352726872\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCPI\" target=\"_blank\">RCPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658161\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Star Scientific (STSI): After failing to hit paydirt with the R.J. Reynolds case, the...</a></h4><p>More on Star Scientific (STSI): After <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/658131\">failing to hit paydirt</a> with the R.J. Reynolds case, the company warns it's in a dire financial situation. On September 30 Star Scientific notes it held $9.5M in cash, and on bringing in fresh funds it says \"there can be no assurance that the company will be successful in obtaining such funding at commercially reasonable terms.\" STSI <font color=\"red\">-18.4%</font> premarket. (PR)</p><div class=\"tiny-share-widget\" data-id=\"658161\" data-linked=\"More on Star Scientific (STSI): After failing to hit paydirt with the R.J. Reynolds case, the...\" data-tweet=\"$RCPI - More on Star Scientific (STSI): After failing to hit paydirt with the R.J. Reynolds case, the company warns it&#39;s in a dire financial situation. On September 30 Star Scientific notes it held $9.5M in cash, and on bringing in fresh funds it says &quot;... https://seekingalpha.com/news/658161?source=tweet\" data-url=\"https://seekingalpha.com/news/658161\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658151\" data-ts=\"1352726798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VVUS\" target=\"_blank\">VVUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658151\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vivus&#39;s (NASDAQ:VVUS) Qsymia extended-release capsules improved obstructive sleep apnea...</a></h4><p>Vivus's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/VVUS\" title=\"Vivus, Inc.\">VVUS</a>) Qsymia extended-release capsules <a target=\"_blank\" href=\"http://www.marketwatch.com/story/study-shows-vivus-qsymia-may-help-sleep-apnea-2012-11-12\">improved</a> obstructive sleep apnea (OSA), cardiovascular risk and weight loss in a proof-of-concept study of 45 obese adults. The capsules are FDA-approved for chronic weight management but not OSA. Shares <font color=\"green\">+3.3%</font>. (PR)</p><div class=\"tiny-share-widget\" data-id=\"658151\" data-linked=\"Vivus&#39;s (NASDAQ:VVUS) Qsymia extended-release capsules improved obstructive sleep apnea (OSA),...\" data-tweet=\"$VVUS - Vivus&#39;s (NASDAQ:VVUS) Qsymia extended-release capsules improved obstructive sleep apnea (OSA), cardiovascular risk and weight loss in a proof-of-concept study of 45 obese adults. The capsules are FDA-approved for chronic weight management but no... https://seekingalpha.com/news/658151?source=tweet\" data-url=\"https://seekingalpha.com/news/658151\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658131\" data-ts=\"1352726301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCPI\" target=\"_blank\">RCPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658131\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shares of Star Scientific (STSI) fall 18.4% premarket after the company files its Q3 results...</a></h4><p>Shares of Star Scientific (STSI) <font color=\"red\">fall 18.4%</font> premarket after the company files its Q3 results with the SEC. The biggest disclosure from the company was that it only received $5M in cash in a settlement with R.J. Reynolds in a case that ran on for years.</p><div class=\"tiny-share-widget\" data-id=\"658131\" data-linked=\"Shares of Star Scientific (STSI) fall 18.4% premarket after the company files its Q3 results...\" data-tweet=\"$RCPI - Shares of Star Scientific (STSI) fall 18.4% premarket after the company files its Q3 results with the SEC. The biggest disclosure from the company was that it only received $5M in cash in a settlement with R.J. Reynolds in a case that ran on for... https://seekingalpha.com/news/658131?source=tweet\" data-url=\"https://seekingalpha.com/news/658131\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"658011\" data-ts=\"1352723288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LUK-OLD\" target=\"_blank\">LUK-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/658011\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leucadia (NYSE:LUK-OLD) announces the purchase of the rest of Jefferies (NYSE:JEF), offering...</a></h4><p>Leucadia (NYSE:<a href=\"https://seekingalpha.com/symbol/LUK-OLD\" title=\"Leucadia National Corporation\">LUK-OLD</a>) announces the purchase of the rest of Jefferies (NYSE:<a href=\"https://seekingalpha.com/symbol/JEF\" title=\"Jefferies Group Inc.\">JEF</a>), offering 0.81 of a share of Leucadia for each share of Jefferies. Jefferies CEO Dick Handler will become CEO of Leucadia. Leucadia already owns 28.6% of Jefferies. LUK shares<font color=\"green\"> +2.4%</font> premarket. JEF shares<font color=\"green\"> +22%</font> premarket. (PR)</p><div class=\"tiny-share-widget\" data-id=\"658011\" data-linked=\"Leucadia (NYSE:LUK-OLD) announces the purchase of the rest of Jefferies (NYSE:JEF), offering...\" data-tweet=\"$LUK-OLD - Leucadia (NYSE:LUK-OLD) announces the purchase of the rest of Jefferies (NYSE:JEF), offering 0.81 of a share of Leucadia for each share of Jefferies. Jefferies CEO Dick Handler will become CEO of Leucadia. Leucadia already owns 28.6% of Jeffe... https://seekingalpha.com/news/658011?source=tweet\" data-url=\"https://seekingalpha.com/news/658011\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"657701\" data-ts=\"1352710093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/657701\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Asian and European shares are mixed, with sentiment boosted by China&#39;s wider-than-expected trade...</a></h4><p>Asian and European shares are <a target=\"_blank\" href=\"http://www.cnbc.com/id/49785314\">mixed</a>, with sentiment boosted by China's wider-than-expected <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/657391\">trade surplus</a> but hurt by a <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/657671\">contraction</a> in Japan's economy and uncertainty over whether Greece will finally receive approval for the latest tranche of its bailout at a meeting of eurozone finmins today. Japan <font color=\"red\">-0.9%</font>, Hong Kong <font color=\"green\">+0.2%</font>, China <font color=\"green\">+0.5%</font>, India <font color=\"red\">-0.2%</font>. Euro Stoxx 50 <font color=\"red\">-0.2%</font>, London <font color=\"green\">+0.2%</font>, Paris <font color=\"red\">-0.2%</font>, Frankfurt <font color=\"green\">+0.2%</font>, Milan <font color=\"green\">+0.1%</font>, Madrid <font color=\"red\">-0.4%</font>.</p><div class=\"tiny-share-widget\" data-id=\"657701\" data-linked=\"Asian and European shares are mixed, with sentiment boosted by China&#39;s wider-than-expected trade...\" data-tweet=\"Asian and European shares are mixed, with sentiment boosted by China&#39;s wider-than-expected trade surplus but hurt by a contraction in Japan&#39;s economy and uncertainty over whether Greece will finally receive approval for the latest tranche of its bailout... https://seekingalpha.com/news/657701?source=tweet\" data-url=\"https://seekingalpha.com/news/657701\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:48 AM </div></div></li>","count":54,"message":null,"success":true,"today":{"start":1576645200,"end":1576731599,"str":"Wednesday, December 18, 2019"},"yesterday":{"start":1576558800,"end":1576645199}}